A multicellular basis for the origination of blast crisis in chronic myeloid leukemia

Cancer Research

Volumn 71, Issue 8, 2011, Pages 2838-2847

  Sachs, Rainer K ^a   Johnsson, Kerstin ^a   Hahnfeldt, Philip ^b   Luo, Janet ^a   Chen, Allen ^a   Hlatky, Lynn ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB;

ARTICLE; BLAST CELL; BLAST CELL CRISIS; CELL INTERACTION; CHRONIC MYELOID LEUKEMIA; LEUKEMIA CELL; MATHEMATICAL MODEL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

BLAST CRISIS; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MODELS, BIOLOGICAL;

EID: 79954570748     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4600     Document Type: Article

References (48)

1. Carella A, Daley G, Eaves C, Goldman J, Hehlmann R. Chronic myeloid leukaemia: Biology and treatment. London, UK: Martin Dunitz; 2001. p. 205-23.
2. Cortes J, Deininger M. Chronic myeloid leukemia. New York: Informa; 2007.
3. Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007;370:342-50. (Pubitemid 47094995)
4. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 2009;113:1619-30.
5. Whichard ZL, Sarkar CA, Kimmel M, Corey SJ. Hematopoiesis and its disorders: A systems biology approach. Blood 2010;115:2339-47.
6. Hehlmann R, Berger U, Hochhaus A. Chronic myeloid leukemia: A model for oncology. Ann Hematol 2005;84:487-97. (Pubitemid 41007019)
7. Hehlmann R, Saussele S. Treatment of chronic myeloid leukemia in blast crisis. Haematologica 2008;93:1765-9.
8. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53. (Pubitemid 46823444)
9. Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F. Eradication of chronic myeloid leukemia stem cells: A novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 2009;5:e1000503.
10. Morrison SJ, Uchida N, Weissman IL. The biology of hematopoietic stem cells. Annu Rev Cell Dev Biol 1995;11:35-71. (Pubitemid 26019601)
11. Dingli D, Traulsen A, Michor F. (A)symmetric stem cell replication and cancer. PLoS Comput Biol 2007;3:e53.
12. Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature 2005;435:1267-70. (Pubitemid 40943094)
13. Michor F. Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia. Trends Pharmacol Sci 2007;28:197-9. (Pubitemid 46661002)
14. Roeder I, d'Inverno M. New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia. Blood Cells Mol Dis 2009;43:88-97.
15. Stuart SA, Minami Y, Wang JY. The CML stem cell: Evolution of the progenitor. Cell Cycle 2009;8:1338-43.
16. Michor F. Chronic myeloid leukemia blast crisis arises from progenitors. Stem Cells 2007;25:1114-8. (Pubitemid 46684870)
17. Reid AG, De Melo VA, Elderfield K, Clark I, Marin D, Apperley J, Naresh KN. Phenotype of blasts in chronic myeloid leukemia in blastic phase- Analysis of bone marrow trephine biopsies and correlation with cytogenetics. Leuk Res 2009;33:418-25.
18. Radich JP. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program 2007;1:384-91.
19. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-22. (Pubitemid 38685338)
20. Koptyra M, Cramer K, Slupianek A, Richardson C, Skorski T. BCR/ ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress. Leukemia 2008;22:1969-72.
21. Motoji T. Immunophenotypes on blast cells of chronic myelogenous leukemia. Nippon Rinsho 2001;59:2342-7.
22. Oh SH, Park TS, Kim HR, Lee JY, Kim JH, Shin JH, et al. Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia. Leuk Res 2009;33:e195- 8.
23. Pullarkat ST, Vardiman JW, Slovak ML, Rao DS, Rao NP, Bedell V, et al. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leuk Res 2008;32:1770-5.
24. Westfall DE, Zhang L, Song S, Lee S. Concurrent megakaryocytic and erythroid chronic myelogenous leukemia blast crisis. Arch Pathol Lab Med 2008;132:1021-5. (Pubitemid 351918711)
25. Bhowmick NA, Moses HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005;15:97-101. (Pubitemid 40127637)
26. Sachs RK, Chan M, Hlatky L, Hahnfeldt P. Modeling intercellular interactions during carcinogenesis. Radiat Res 2005;164:324-31. (Pubitemid 41233787)
27. Almog N, Ma L, Raychowdhury R, Schwager C, Erber R, Short S, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009;69:836-44.
28. Trosko JE. From adult stem cells to cancer stem cells: Oct-4 Gene, cell-cell communication, and hormones during tumor promotion. Ann N Y Acad Sci 2006;1089:36-58. (Pubitemid 47092073)
29. Wodarz D. Stem cell regulation and the development of blast crisis in chronic myeloid leukemia: Implications for the outcome of Imatinib treatment and discontinuation. Med Hypotheses 2008;70:128-136. (Pubitemid 350161156)
30. Moore H, Li NK. A mathematical model for chronic myelogenous leukemia (CML) and T cell interaction. J Theor Biol 2004;227:513-23. (Pubitemid 38376168)
31. Kim PS, Lee PP, Levy D. Dynamics and potential impact of the immune response to chronic myelogenous leukemia. PLoS Comput Biol 2008;4:e1000095.
32. Walker MR, Patel KK, Stappenbeck TS. The stem cell niche. J Pathol 2009;217:169-80.
33. Kirouac DC, Madlambayan GJ, Yu M, Sykes EA, Ito C, Zandstra PW. Cell-cell interaction networks regulate blood stem and progenitor cell fate. Mol Syst Biol 2009;5:293.
34. Carlesso N, Cardoso AA. Stem cell regulatory niches and their role in normal and malignant hematopoiesis. Curr Opin Hematol 2010;17: 281-6.
35. Baker SG, Kramer BS. Paradoxes in carcinogenesis: New opportunities for research directions. BMC Cancer 2007;7:151.
36. Sokal JE. Prognosis in chronic myeloid leukaemia: Biology of the disease vs. treatment. Baillieres Clin Haematol 1987;1:907-29.
37. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc Natl Acad Sci U S A 1999;96:3120-5. (Pubitemid 29148854)
38. Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, et al. Sudden onset of the blastic phase of chronic myelogenous leukemia: Patterns and implications. Cancer 2003;98:81-5. (Pubitemid 36741129)
39. Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800-2.
40. Little MP, Weiss HA, Boice JD Jr, Darby SC, Day NE, Muirhead CR. Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis. Radiat Res 1999;152:280-92. (Pubitemid 29413664)
41. Little MP, Hoel DG, Molitor J, Boice JD, Wakeford R, Muirhead CR. New models for evaluation of radiation-induced lifetime cancer risk and its uncertainty employed in the UNSCEAR 2006 report. Radiat Res 2008;169:660-76. (Pubitemid 351793456)
42. Richardson D, Sugiyama H, Nishi N, Sakata R, Shimizu Y, Grant EJ, et al. Ionizing radiation and leukemia mortality among Japanese Atomic Bomb Survivors, 1950-2000. Radiat Res 2009;172:368-82.
43. Saussele S, Lauseker M, Pfirrmann M, Leitner A, Pletsch N, Stegelmann F, et al. Evolution of blast crisis (BC) in chronic myeloid leukemia (CML) in the imatinib-era: A rare event with high proportions of low risk patients and of early Bc; need for rapid detection. results of the German CML Study IV. Blood 2009;114: 3287[abstract].
44. Kim PS, Lee PP, Levy D. Modeling imatinib-treated chronic myelogenous leukemia: Reducing the complexity of agent-based models. Bull Math Biol 2008;70:728-44.
45. Roeder I, Horn M, Glauche I, Hochhaus A, Mueller MC, Loeffler M. Dynamic modeling of imatinib-treated chronic myeloid leukemia: Functional insights and clinical implications. Nat Med 2006;12: 1181-4. (Pubitemid 44527354)
46. Lenaerts T, Pacheco JM, Traulsen A, Dingli D. Tyrosine kinase inhibitor therapy can cure chronic myeloid leukemia without hitting leukemic stem cells. Haematologica 2010;95:900-7.
47. Komarova NL, Wodarz D. Combination therapies against chronic myeloid leukemia: Short-term versus long-term strategies. Cancer Res 2009;69:4904-10.
48. Ainseba B, Benosman C. Optimal control for resistance and suboptimal response in CML. Math Biosci 2010;227:81-93.